IP Library Granted Patent US 8,609,353
Granted Patent B2
US 8,609,353 · App. 12/160,610 · Granted Dec 17, 2013

Diagnostics and methods for removal and detection of interferents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,353
App. No.
12/160,610
Granted
Dec 17, 2013
Kind
B2
Abstract

Described herein are substrates, methods, articles, and kits that are useful for removing interferents from samples for diagnostic purposes. The interferents are removed with phosphocellulose and cation exchange materials. These materials could also be used in vitro to improve the performance of a diagnostic assay or in vivo to remove the interferents.

Claims (32)

1. A method of removing at least one interferent from a sample comprising contacting a peptide to said sample, thereby removing said interferent, wherein the interferent comprises elastase and wherein said elastase is capable of detection by a peptide comprising the amino acid sequence PFPQANYITY (SEQ ID NO. 1).

2. The method of claim 1 , wherein said sample is selected from the group consisting of wound, tissue, urine, saliva, blood, and stool samples.

3. The method of claim 1 , wherein said sample is selected from the group consisting of fluid, biopsy and solid samples.

4. The method of claim 1 , wherein said interferent is removed prior to an immunostaining or a PCR reaction.

5. The method of claim 1 , wherein said peptide is applied to a gauze, cleansing wipe, bead, glass frit, swab, wipe, pad, membrane, a non-woven fiber, a sponge, a filter, or a dressing prior to contact to said sample.

6. The method of claim 1 , wherein said peptide is incorporated into a biopsy punch device prior to contact to said sample.

7. The method of claim 1 , wherein said peptide is applied to a lateral flow assay device prior to contact to said sample.

8. The method of claim 1 , wherein said peptide is incorporated into a collection container, a collection device, a tube, a vial, or a cassette prior to diagnostic testing.

9. A method of removing at least one interferent from a sample comprising contacting a peptide to said sample, thereby removing said interferent, wherein the interferent comprises papain wherein said papain is capable of detection by a peptide comprising the amino add sequence of PMPPLCTSM (SEQ ID NO. 2).

10. The method of claim 9 , wherein said sample is selected from the group consisting of wound, tissue, urine, saliva, blood, and stool samples.

11. The method of claim 9 , wherein said sample is selected from the group consisting of fluid, biopsy and solid samples.

12. The method of claim 9 , wherein said interferent is removed prior to an immunostaining or a PCR reaction.

13. The method of claim 1 , wherein said papain is applied to a gauze, cleansing wipe, bead, glass frit, swab, wipe, pad, membrane, a non-woven fiber, a sponge, a filter, or a dressing prior to contact to said sample.

14. The method of claim 1 , wherein said papain is incorporated into a biopsy punch device prior to contact to said sample.

15. The method of claim 1 , wherein said papain is applied to a lateral flow assay device prior to contact to said sample.

16. The method of claim 1 , wherein said papain is incorporated into a collection container, a collection device, a tube, a vial, or a cassette prior to diagnostic testing.

17. A method of removing at least one interferent from a sample comprising contacting a peptide to said sample, thereby removing said interferent, wherein the interferent comprises elastase, and wherein the peptide is capable of detection by a peptide comprising amino acid sequence H 2 N-PFPQANYITYCV-OH (SEQ ID No:9).

18. The method of claim 17 , wherein said sample is selected from the group consisting of wound, tissue, urine, saliva, blood, and stool samples.

19. The method of claim 17 , wherein said sample is selected from the group consisting of fluid, biopsy and solid samples.

20. The method of claim 17 , wherein said interferent is removed prior to an immunostaining or a PCR reaction.

21. The method of claim 17 , wherein said peptide is applied to a gauze, cleansing wipe, bead, glass frit, swab, wipe, pad, membrane, a non -woven fiber, a sponge, a filter, or a dressing prior to contact to said sample.

22. The method of claim 17 , wherein said peptide is incorporated into a biopsy punch device prior to contact to said sample.

23. The method of claim 17 , wherein said peptide is applied to a lateral flow assay device prior to contact to said sample.

24. The method of claim 17 , wherein said peptide is incorporated into a collection container, a collection device, a tube, a vial, or a cassette prior to diagnostic testing.

25. A method of removing at least one interferent from a sample comprising contacting a peptide to said sample, thereby removing said interferent, wherein the interferent comprises papain and wherein said papain is capable of detection by a peptide comprising the amino acid sequence (NH 2 -E(Edans)PMPPLCTSMK(Dabcyl)-COOH) (SEQ ID No:10).

26. The method of claim 25 , wherein said sample is selected from the group consisting of wound, tissue, urine, saliva, blood, and stool samples.

27. The method of claim 25 , wherein said sample is selected from the group consisting of fluid, biopsy and solid samples.

28. The method of claim 25 , wherein said interferent is removed prior to an immunostaining or a PCR reaction.

29. The method of claim 25 , wherein said cation material or phosphocel iulose is applied to a gauze, cleansing wipe, bead, glass frit, swab, wipe, pad, membrane, a non-woven fiber, a sponge, a filter, or a dressing prior to contact to said sample.

30. The method of claim 25 , wherein said peptide is incorporated into a biopsy punch device prior to contact to said sample.

31. The method of claim 25 , wherein said peptide is applied to a lateral flow assay device prior to contact to said sample.

32. The method of claim 25 , wherein said peptide membrane or phosphocellulose is incorporated into a collection container, a collection device, a tube, a vial, or a cassette prior to diagnostic testing.

Assignments (5)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Feb 6, 2017
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: KCI LICENSING, INC., AS GRANTOR; TECHNIMOTION, LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS GRANTOR; SYSTAGENIX WOUND MANAGEMENT (US), INC., A DELAWARE CORPORATION, AS GRANTOR
Reel/Frame 041395/0044 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY PREVIOUSLY RECORDED AT REEL: 033699 FRAME: 0186. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 18, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHEK LABORATORIES (US), INC.
Reel/Frame 033773/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHECK LABORATORIES (US), INC.
Reel/Frame 033699/0186 →
SECURITY AGREEMENT Recorded Oct 29, 2013
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 031508/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2010
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL, LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 024823/0245 →